Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05960955 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Cadonilimab
DRUG: AK117
DRUG: Oxaliplatin
DRUG: Tegafur-gimeracil-oteracil potassium
DRUG: Docetaxel
DRUG: 5-Fluorouracil

Sponsor

Akeso